Skip to content

Author

Marcela V. Maus

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

BIOM-14 Patterns, risk factors and management of CD19-directed Chimeric Antigen Receptor T-cell therapy failure in CNS lymphoma

CD19-directed chimeric antigen receptor T-cell therapy (CD19-CAR) demonstrates encouraging activity in CNS lymphoma (CNSL), yet most patients ultimately develop progressive disease (PD). Predictors, radiographic patterns, and optimal salvage strategies after CD19-CAR failure remain poorly defined. We retrospectively...

L. Kaulen, P. Karschnia, S. Doubrovinskaia et al. · 0 citations
Open access Sep 2026

Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System

Objective To compare the real-world safety profiles of lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) in patients with diffuse large B-cell lymphoma, leveraging data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. Patients and Methods Case...

Magdi Elsallab, M. Lunning, Moataz Ellithi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.